Leah Neufeld Buys 2,626 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) insider Leah Neufeld purchased 2,626 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was purchased at an average cost of $4.15 per share, with a total value of $10,897.90. Following the acquisition, the insider owned 25,970 shares in the company, valued at approximately $107,775.50. This represents a 11.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Immuneering Price Performance

Shares of IMRX stock opened at $4.58 on Friday. Immuneering Corporation has a one year low of $1.10 and a one year high of $10.08. The stock has a fifty day moving average price of $6.37 and a 200 day moving average price of $5.78. The stock has a market cap of $295.73 million, a P/E ratio of -2.57 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Equities research analysts anticipate that Immuneering Corporation will post -1.86 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. Leerink Partners assumed coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Mizuho set a $12.00 price objective on shares of Immuneering in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Institutional Investors Weigh In On Immuneering

A number of hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Immuneering during the third quarter worth approximately $35,000. Future Financial Wealth Managment LLC acquired a new position in Immuneering during the 3rd quarter worth $35,000. Mercer Global Advisors Inc. ADV bought a new position in Immuneering in the 3rd quarter valued at $70,000. Moors & Cabot Inc. acquired a new stake in shares of Immuneering in the 3rd quarter valued at $77,000. Finally, Virtu Financial LLC bought a new stake in shares of Immuneering during the third quarter worth $98,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.